Ebp1 expression in benign and malignant prostate

Cancer Cell International

Volumn 8, Issue , 2008, Pages

  Gannon, Philippe O ^a   Koumakpayi, Ismaël Hervé ^a   Le Page, Cécile ^a   Karakiewicz, Pierre I ^b   Mes Masson, Anne Marie ^a,c   Saad, Fred ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BINDING PROTEIN; CYCLIN D1; EBP1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 58149504204     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-8-18     Document Type: Article

References (35)

1. Jemal A Siegel R Ward E Murray T Xu J Thun MJ Cancer statistics, 2007 CA Cancer J Clin 2007, 57(1):43-66. 17237035
2. Pound CR Partin AW Eisenberger MA Chan DW Pearson JD Walsh PC Natural history of progression after PSA elevation following radical prostatectomy JAMA 1999, 281(17):1591-1597. 10.1001/jama.281.17.1591 10235151
3. Han M Partin AW Zahurak M Piantadosi S Epstein JI Walsh PC Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 2003, 169(2):517-523. 10.1016/S0022-5347(05)63946-8 12544300
4. Koumakpayi IH Diallo JS Le Page C Lessard L Gleave M Begin LR Mes-Masson AM Saad F Expression and nuclear localization of erbb3 in prostate cancer Clin Cancer Res 2006, 12(9):2730-2737. 10.1158/ 1078-0432.CCR-05-2242 16675564
5. Koumakpayi IH Diallo JS Le Page C Lessard L Filali-Mouhim A Begin LR Mes-Masson AM Saad F Low nuclear erbb3 predicts biochemical recurrence in patients with prostate cancer BJU Int 2007, 100(2):303-309. 10.1111/ j.1464-410X.2007.06992.x 17532856
6. Cheng CJ Ye XC Vakar-Lopez F Kim J Tu SM Chen DT Navone NM Yu-Lee LY Lin SH Hu MC Bone microenvironment and androgen status modulate subcellular localization of erbb3 in prostate cancer cells Mol Cancer Res 2007, 5(7):675-684. 2000833 17634423 10.1158/1541-7786.MCR-06-0306
7. Yoo JY Wang XW Rishi AK Lessor T Xia XM Gustafson TA Hamburger AW Interaction of the PA2G4 (EBP1) protein with erbb-3 and regulation of this binding by heregulin Br J Cancer 2000, 82(3):683-690. 10.1054/ bjoc.1999.0981 10682683
8. Xia X Lessor TJ Zhang Y Woodford N Hamburger AW Analysis of the expression pattern of Ebp1, an erbb-3-binding protein Biochem Biophys Res Commun 2001, 289(1):240-244. 10.1006/bbrc.2001.5942 11708806
9. Lessor TJ Yoo JY Xia X Woodford N Hamburger AW Ectopic expression of the erbb-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines J Cell Physiol 2000, 183(3):321-329. 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O 10797306
10. Zhang Y Fondell JD Wang Q Xia X Cheng A Lu ML Hamburger AW Repression of androgen receptor mediated transcription by the erbb-3 binding protein, Ebp1 Oncogene 2002, 21(36):5609-5618. 10.1038/sj.onc.1205638 12165860
11. Zhang Y Woodford N Xia X Hamburger AW Repression of E2F1-mediated transcription by the erbb3 binding protein Ebp1 involves histone deacetylases Nucleic Acids Res 2003, 31(8):2168-2177. 153746 12682367 10.1093/nar/gkg318
12. Zhang Y Wang XW Jelovac D Nakanishi T Yu MH Akinmade D Goloubeva O Ross DD Brodie A Hamburger AW The erbb3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells Proc Natl Acad Sci USA 2005, 102(28):9890-9895. 1175001 15994225 10.1073/pnas.0503829102
13. Zhang Y Akinmade D Hamburger AW The erbb3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription Nucleic Acids Res 2005, 33(18):6024-6033. 1270947 16254079 10.1093/nar/gki903
14. Santegoets SJ Schreurs MW Reurs AW Lindenberg JJ Kueter EW Eertwegh van den AJ Hooijberg E Brandwijk RJ Hufton SE Hoogenboom HR Identification and Characterization of erbb-3-Binding Protein-1 as a Target for Immunotherapy J Immunol 2007, 179(3):2005-2012. 17641068
15. Le Page C Koumakpayi IH Alam-Fahmy M Mes-Masson AM Saad F Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients Br J Cancer 2006, 94(12):1906-1912. 10.1038/ sj.bjc.6603184 16721361
16. Diallo JS Aldejmah A Mouhim AF Peant B Fahmy MA Koumakpayi IH Sircar K Begin LR Mes-Masson AM Saad F NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model Clin Cancer Res 2007, 13(23):7044-7052. 10.1158/ 1078-0432.CCR-07-1224 18056181
17. Gown AM Vogel AM Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues Am J Pathol 1984, 114(2):309-321. 1900342 6320650
18. Gannon PO Alam Fahmy M Begin LR Djoukhadjian A Filali-Mouhim A Lapointe R Mes-Masson AM Saad F Presence of prostate cancer metastasis correlates with lower lymph node reactivity Prostate 2006, 66(16):1710-1720. 10.1002/pros.20466 16955408
19. Dhanasekaran SM Barrette TR Ghosh D Shah R Varambally S Kurachi K Pienta KJ Rubin MA Chinnaiyan AM Delineation of prognostic biomarkers in prostate cancer Nature 2001, 412(6849):822-826. 10.1038/35090585 11518967
20. Rhodes DR Sanda MG Otte AP Chinnaiyan AM Rubin MA Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer J Natl Cancer Inst 2003, 95(9):661-668. 12734317
21. Freedland SJ Humphreys EB Mangold LA Eisenberger M Dorey FJ Walsh PC Partin AW Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy Jama 2005, 294(4):433-439. 10.1001/jama.294.4.433 16046649
22. Shuford MD Cookson MS Chang SS Shintani AK Tsiatis A Smith JA Jr Shappell SB Adverse prognostic significance of capsular incision with radical retropubic prostatectomy J Urol 2004, 172(1):119-123. 10.1097/ 01.ju.0000132137.02846.ec 15201750
23. Zhang Y Hamburger AW Heregulin regulates the ability of the erbb3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription J Biol Chem 2004, 279(25):26126-26133. 10.1074/jbc.M314305200 15073182
24. Squatrito M Mancino M Donzelli M Areces LB Draetta GF EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes Oncogene 2004, 23(25):4454-4465. 10.1038/ sj.onc.1207579 15064750
25. Liu Z Ahn JY Liu X Ye K Ebp1 isoforms distinctively regulate cell survival and differentiation Proc Natl Acad Sci USA 2006, 103(29):10917-10922. 1544149 16832058 10.1073/pnas.0602923103
26. Schafer W Funke PJ Kunde D Rausch U Wennemuth G Stutzer H Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: Correlation with clinical data of long-term observations J Urol 2006, 176(2):532-537. 10.1016/j.juro.2006.03.033 16813883
27. Ruizeveld de Winter JA Janssen PJ Sleddens HM Verleun-Mooijman MC Trapman J Brinkmann AO Santerse AB Schroder FH Kwast van der TH Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am J Pathol 1994, 144(4):735-746. 1887232 7512791
28. Lee D High androgen receptor levels are predictive of decreased survival in prostate cancer Clin Prostate Cancer 2003, 2(1):13-14. 15046676
29. Noordzij MA Bogdanowicz JF van Krimpen C Kwast van der TH van Steenbrugge GJ The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients J Urol 1997, 158(5):1880-1884. discussion 1884-1885. 10.1016/ S0022-5347(01)64157-0 9334622
30. Chandran UR Dhir R Ma C Michalopoulos G Becich M Gilbertson J Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors BMC Cancer 2005, 5(1):45. 1173092 15892885 10.1186/ 1471-2407-5-45
31. Woenckhaus M Grepmeier U Wild PJ Merk J Pfeifer M Woenckhaus U Stoelcker B Blaszyk H Hofstaedter F Dietmaier W Multitarget FISH and LOH analyses at chromosome 3p in non-small cell lung cancer and adjacent bronchial epithelium Am J Clin Pathol 2005, 123(5):752-761. 10.1309/ C4BK7GQV8E5XU2TL 15981815
32. Ayala G Thompson T Yang G Frolov A Li R Scardino P Ohori M Wheeler T Harper W High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence Clin Cancer Res 2004, 10(19):6572-6578. 10.1158/ 1078-0432.CCR-04-0477 15475446
33. Paik S Shak S Tang G Kim C Baker J Cronin M Baehner FL Walker MG Watson D Park T A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 2004, 351(27):2817-2826. 10.1056/NEJMoa041588 15591335
34. Schmidt U Fuessel S Koch R Baretton GB Lohse A Tomasetti S Unversucht S Froehner M Wirth MP Meye A Quantitative multi-gene expression profiling of primary prostate cancer Prostate 2006, 66(14):1521-1534. 10.1002/ pros.20490 16921506
35. Laxman B Morris DS Yu J Siddiqui J Cao J Mehra R Lonigro RJ Tsodikov A Wei JT Tomlins SA A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Cancer Res 2008, 68(3):645-649. 10.1158/0008-5472.CAN-07-3224 18245462